{"id":"NCT02782741","sponsor":"Genzyme, a Sanofi Company","briefTitle":"Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","officialTitle":"A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-02","primaryCompletion":"2020-03-19","completion":"2023-05-31","firstPosted":"2016-05-25","resultsPosted":"2021-04-08","lastUpdate":"2024-04-04"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glycogen Storage Disease Type II;Pompe's Disease"],"interventions":[{"type":"DRUG","name":"Avalglucosidase alfa (GZ402666)","otherNames":[]},{"type":"DRUG","name":"Alglucosidase alfa (GZ419829)","otherNames":["Myozyme","Lumizyme"]}],"arms":[{"label":"avalglucosidase alfa (GZ402666)","type":"EXPERIMENTAL"},{"label":"alglucosidase alfa (GZ419829)","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa.\n\nSecondary Objective:\n\nTo determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).","primaryOutcome":{"measure":"PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49","timeFrame":"Baseline, Week 49","effectByArm":[{"arm":"PAP: Avalglucosidase Alfa","deltaMin":2.89,"sd":0.88},{"arm":"PAP: Alglucosidase Alfa","deltaMin":0.46,"sd":0.93}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0074"},{"comp":"OG000 vs OG001","p":"0.0626"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Russia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["40817977","37559825","37036722","34800399"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":51},"commonTop":["Headache","Nasopharyngitis","Arthralgia","Back Pain","Diarrhoea"]}}